Application Highlight
Employing PSI™ to Identify Optimal Bi-Specific Antibody Candidates

Learn how PSI can help you reveal functional immune-tumor interaction and mechanism of therapy to advise lead choice.

Application of bispecific antibody constructs to improve immunotherapy success

Recent clinical progress in immunooncology significantly improved clinical outcomes for many patients with hard-to-treat malignant tumors, leading to partial and complete remission and long-term survival in a fraction of patients. However, a large number of patients do not respond to these treatments, creating an urgent need for novel strategies to enhance the efficacy of immunotherapies.

Download Resource

Your Data is Secure

We will always keep your personal information safe and not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.

In this Application Highlight we discuss:
  • Highlight the use of IsoPlexis’ Polyfunctional Strength Index, PSI™, a single-cell cytokinebased metric of cellular potency, in the context of pre-clinical assessment of bispecific antibodies
  • Identify subtle differences in quality of novel bispecific antibody constructs relative to controls, utilizing the PSI of the potent T cell subsets engaged
  • Demonstrate that PSI can improve the choice of lead bispecific immunotherapeutic products by identifying key differences in the therapies’ cytokine-based mechanisms at the single-cell level

Employing PSI™ to Identify Optimal Bi-Specific Antibody Candidates

Learn how PSI can help you reveal functional immune-tumor interaction and mechanism of therapy to advise lead choice. Application of bispecific antibody constructs to improve immunotherapy success Recent clinical progress in immunooncology significantly improved clinical outcomes for many patients with hard-to-treat malignant tumors, leading to partial and complete remission and long-term survival in a fraction of patients. However, a large number of patients do not respond to these treatments, creating an urgent need for novel strategies to enhance the efficacy of immunotherapies.

IsoPlexis Awards